{"title":"靶向EBV编码产物：对EBV相关疾病药物开发的意义。","authors":"Mengwen Lv, Yuan Ding, Yan Zhang, Shuzhen Liu","doi":"10.1002/rmv.2487","DOIUrl":null,"url":null,"abstract":"<p><p>Epstein-Barr virus, a human gamma-herpesvirus, has a close connection to the pathogenesis of cancers and other diseases, which are a burden for public health worldwide. So far, several drugs or biomolecules have been discovered that can target EBV-encoded products for treatment, such as Silvestrol, affinity toxin, roscovitine, H20, H31, curcumin, thymoquinone, and ribosomal protein L22. These drugs activate or inhibit the function of some biomolecules, affecting subsequent signalling pathways by acting on the products of EBV. These drugs usually target LMP1, LMP2; EBNA1, EBNA2, EBNA3; EBER1, EBER2; Bam-HI A rightward transcript and BHRF1. Additionally, some promising findings in the fields of vaccines, immunological, and cellular therapies have been established. In this review, we mainly summarise the function of drugs mentioned above and unique mechanisms, hoping that we can help giving insight to the design of drugs for the treatment of EBV-associated diseases.</p>","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":" ","pages":"e2487"},"PeriodicalIF":9.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Targeting EBV-encoded products: Implications for drug development in EBV-associated diseases.\",\"authors\":\"Mengwen Lv, Yuan Ding, Yan Zhang, Shuzhen Liu\",\"doi\":\"10.1002/rmv.2487\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Epstein-Barr virus, a human gamma-herpesvirus, has a close connection to the pathogenesis of cancers and other diseases, which are a burden for public health worldwide. So far, several drugs or biomolecules have been discovered that can target EBV-encoded products for treatment, such as Silvestrol, affinity toxin, roscovitine, H20, H31, curcumin, thymoquinone, and ribosomal protein L22. These drugs activate or inhibit the function of some biomolecules, affecting subsequent signalling pathways by acting on the products of EBV. These drugs usually target LMP1, LMP2; EBNA1, EBNA2, EBNA3; EBER1, EBER2; Bam-HI A rightward transcript and BHRF1. Additionally, some promising findings in the fields of vaccines, immunological, and cellular therapies have been established. In this review, we mainly summarise the function of drugs mentioned above and unique mechanisms, hoping that we can help giving insight to the design of drugs for the treatment of EBV-associated diseases.</p>\",\"PeriodicalId\":21180,\"journal\":{\"name\":\"Reviews in Medical Virology\",\"volume\":\" \",\"pages\":\"e2487\"},\"PeriodicalIF\":9.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reviews in Medical Virology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/rmv.2487\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/10/31 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in Medical Virology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/rmv.2487","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
EB病毒是一种人类γ疱疹病毒，与癌症和其他疾病的发病机制密切相关，这些疾病是全球公共卫生的负担。到目前为止，已经发现了几种可以靶向EBV编码的产物进行治疗的药物或生物分子，如西尔维斯特醇、亲和毒素、roscovitine、H20、H31、姜黄素、胸腺醌和核糖体蛋白L22。这些药物激活或抑制一些生物分子的功能，通过作用于EBV的产物来影响随后的信号通路。这些药物通常靶向LMP1、LMP2；EBNA1、EBNA2、EBNA3；EBER1、EBER2；Bam HI A向右转录本和BHRF1。此外，在疫苗、免疫学和细胞疗法领域也有一些有希望的发现。在这篇综述中，我们主要总结了上述药物的作用和独特的机制，希望有助于深入了解治疗EBV相关疾病的药物设计。
Targeting EBV-encoded products: Implications for drug development in EBV-associated diseases.
Epstein-Barr virus, a human gamma-herpesvirus, has a close connection to the pathogenesis of cancers and other diseases, which are a burden for public health worldwide. So far, several drugs or biomolecules have been discovered that can target EBV-encoded products for treatment, such as Silvestrol, affinity toxin, roscovitine, H20, H31, curcumin, thymoquinone, and ribosomal protein L22. These drugs activate or inhibit the function of some biomolecules, affecting subsequent signalling pathways by acting on the products of EBV. These drugs usually target LMP1, LMP2; EBNA1, EBNA2, EBNA3; EBER1, EBER2; Bam-HI A rightward transcript and BHRF1. Additionally, some promising findings in the fields of vaccines, immunological, and cellular therapies have been established. In this review, we mainly summarise the function of drugs mentioned above and unique mechanisms, hoping that we can help giving insight to the design of drugs for the treatment of EBV-associated diseases.
期刊介绍：
Reviews in Medical Virology aims to provide articles reviewing conceptual or technological advances in diverse areas of virology. The journal covers topics such as molecular biology, cell biology, replication, pathogenesis, immunology, immunization, epidemiology, diagnosis, treatment of viruses of medical importance, and COVID-19 research. The journal has an Impact Factor of 6.989 for the year 2020.
The readership of the journal includes clinicians, virologists, medical microbiologists, molecular biologists, infectious disease specialists, and immunologists. Reviews in Medical Virology is indexed and abstracted in databases such as CABI, Abstracts in Anthropology, ProQuest, Embase, MEDLINE/PubMed, ProQuest Central K-494, SCOPUS, and Web of Science et,al.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
